Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable with Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial

Shinichiro Nakajima, Hiroyuki Uchida, Robert Bies, Fernando Caravaggio, Takefumi Suzuki, Eric Plitman, Wanna Mar, Philip Gerretsen, Bruce G. Pollock, Benoit H. Mulsant, David C. Mamo, Ariel Graff-Guerrero

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background. Population pharmacokinetics can predict antipsychotic blood concentrations at a given time point prior to a dosage change. Those predicted blood concentrations could be used to estimate the corresponding dopamine D2/3 receptors (D2/3R) occupancy by antipsychotics based on the tight relationship between blood and brain pharmacokinetics. However, this 2-step prediction has never been tested. Methods. Two blood samples were collected at separate time points from 32 clinically stable outpatients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; mean ± SD age: 60.1±7.3 years) to measure plasma concentrations of olanzapine or risperidone at baseline. Then, subjects underwent a dose reduction of olanzapine or risperidone and completed a [11C]-raclopride positron emission tomography scan to measure D2/3R occupancy in the putamen. The plasma concentration at the time of the scan was predicted with the 2 samples based on population pharmacokinetic model, using NONMEM. D2/3R occupancy was then estimated by incorporating the predicted plasma concentration in a hyperbole saturation model. The predicted occupancy was compared to the observed value. Results. The mean (95% CI) prediction errors for the prediction of D2/3R occupancy were -1.76% (-5.11 to 1.58) for olanzapine and 0.64% (-6.18 to 7.46) for risperidone. The observed and predicted D2/3R occupancy levels were highly correlated (r = 0.67, P =. 001 for olanzapine; r = 0.67, P =. 02 for risperidone). Conclusions. D2/3R occupancy levels can be predicted from blood drug concentrations collected prior to dosage change. Although this 2-step model is subject to a small degree of error, it could be used to select oral doses aimed at achieving optimal D2/3R occupancy on an individual basis.

Original languageEnglish (US)
Pages (from-to)212-219
Number of pages8
JournalSchizophrenia Bulletin
Volume42
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

olanzapine
Dopamine D2 Receptors
Risperidone
Antipsychotic Agents
Clinical Trials
Pharmacokinetics
Raclopride
Putamen
Diagnostic and Statistical Manual of Mental Disorders
Positron-Emission Tomography
Population
Schizophrenia
Outpatients
Brain
Pharmaceutical Preparations

Keywords

  • antipsychotics
  • dopamine
  • olanzapine
  • PET
  • population pharmacokinetics
  • prediction
  • risperidone
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable with Minimal Plasma Antipsychotic Concentrations : An Open-Label Clinical Trial. / Nakajima, Shinichiro; Uchida, Hiroyuki; Bies, Robert; Caravaggio, Fernando; Suzuki, Takefumi; Plitman, Eric; Mar, Wanna; Gerretsen, Philip; Pollock, Bruce G.; Mulsant, Benoit H.; Mamo, David C.; Graff-Guerrero, Ariel.

In: Schizophrenia Bulletin, Vol. 42, No. 1, 01.01.2016, p. 212-219.

Research output: Contribution to journalArticle

Nakajima, S, Uchida, H, Bies, R, Caravaggio, F, Suzuki, T, Plitman, E, Mar, W, Gerretsen, P, Pollock, BG, Mulsant, BH, Mamo, DC & Graff-Guerrero, A 2016, 'Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable with Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial', Schizophrenia Bulletin, vol. 42, no. 1, pp. 212-219. https://doi.org/10.1093/schbul/sbv106
Nakajima, Shinichiro ; Uchida, Hiroyuki ; Bies, Robert ; Caravaggio, Fernando ; Suzuki, Takefumi ; Plitman, Eric ; Mar, Wanna ; Gerretsen, Philip ; Pollock, Bruce G. ; Mulsant, Benoit H. ; Mamo, David C. ; Graff-Guerrero, Ariel. / Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable with Minimal Plasma Antipsychotic Concentrations : An Open-Label Clinical Trial. In: Schizophrenia Bulletin. 2016 ; Vol. 42, No. 1. pp. 212-219.
@article{d0ae2081ac5f47d196b4a06462ac4e3b,
title = "Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable with Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial",
abstract = "Background. Population pharmacokinetics can predict antipsychotic blood concentrations at a given time point prior to a dosage change. Those predicted blood concentrations could be used to estimate the corresponding dopamine D2/3 receptors (D2/3R) occupancy by antipsychotics based on the tight relationship between blood and brain pharmacokinetics. However, this 2-step prediction has never been tested. Methods. Two blood samples were collected at separate time points from 32 clinically stable outpatients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; mean ± SD age: 60.1±7.3 years) to measure plasma concentrations of olanzapine or risperidone at baseline. Then, subjects underwent a dose reduction of olanzapine or risperidone and completed a [11C]-raclopride positron emission tomography scan to measure D2/3R occupancy in the putamen. The plasma concentration at the time of the scan was predicted with the 2 samples based on population pharmacokinetic model, using NONMEM. D2/3R occupancy was then estimated by incorporating the predicted plasma concentration in a hyperbole saturation model. The predicted occupancy was compared to the observed value. Results. The mean (95{\%} CI) prediction errors for the prediction of D2/3R occupancy were -1.76{\%} (-5.11 to 1.58) for olanzapine and 0.64{\%} (-6.18 to 7.46) for risperidone. The observed and predicted D2/3R occupancy levels were highly correlated (r = 0.67, P =. 001 for olanzapine; r = 0.67, P =. 02 for risperidone). Conclusions. D2/3R occupancy levels can be predicted from blood drug concentrations collected prior to dosage change. Although this 2-step model is subject to a small degree of error, it could be used to select oral doses aimed at achieving optimal D2/3R occupancy on an individual basis.",
keywords = "antipsychotics, dopamine, olanzapine, PET, population pharmacokinetics, prediction, risperidone, schizophrenia",
author = "Shinichiro Nakajima and Hiroyuki Uchida and Robert Bies and Fernando Caravaggio and Takefumi Suzuki and Eric Plitman and Wanna Mar and Philip Gerretsen and Pollock, {Bruce G.} and Mulsant, {Benoit H.} and Mamo, {David C.} and Ariel Graff-Guerrero",
year = "2016",
month = "1",
day = "1",
doi = "10.1093/schbul/sbv106",
language = "English (US)",
volume = "42",
pages = "212--219",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable with Minimal Plasma Antipsychotic Concentrations

T2 - An Open-Label Clinical Trial

AU - Nakajima, Shinichiro

AU - Uchida, Hiroyuki

AU - Bies, Robert

AU - Caravaggio, Fernando

AU - Suzuki, Takefumi

AU - Plitman, Eric

AU - Mar, Wanna

AU - Gerretsen, Philip

AU - Pollock, Bruce G.

AU - Mulsant, Benoit H.

AU - Mamo, David C.

AU - Graff-Guerrero, Ariel

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background. Population pharmacokinetics can predict antipsychotic blood concentrations at a given time point prior to a dosage change. Those predicted blood concentrations could be used to estimate the corresponding dopamine D2/3 receptors (D2/3R) occupancy by antipsychotics based on the tight relationship between blood and brain pharmacokinetics. However, this 2-step prediction has never been tested. Methods. Two blood samples were collected at separate time points from 32 clinically stable outpatients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; mean ± SD age: 60.1±7.3 years) to measure plasma concentrations of olanzapine or risperidone at baseline. Then, subjects underwent a dose reduction of olanzapine or risperidone and completed a [11C]-raclopride positron emission tomography scan to measure D2/3R occupancy in the putamen. The plasma concentration at the time of the scan was predicted with the 2 samples based on population pharmacokinetic model, using NONMEM. D2/3R occupancy was then estimated by incorporating the predicted plasma concentration in a hyperbole saturation model. The predicted occupancy was compared to the observed value. Results. The mean (95% CI) prediction errors for the prediction of D2/3R occupancy were -1.76% (-5.11 to 1.58) for olanzapine and 0.64% (-6.18 to 7.46) for risperidone. The observed and predicted D2/3R occupancy levels were highly correlated (r = 0.67, P =. 001 for olanzapine; r = 0.67, P =. 02 for risperidone). Conclusions. D2/3R occupancy levels can be predicted from blood drug concentrations collected prior to dosage change. Although this 2-step model is subject to a small degree of error, it could be used to select oral doses aimed at achieving optimal D2/3R occupancy on an individual basis.

AB - Background. Population pharmacokinetics can predict antipsychotic blood concentrations at a given time point prior to a dosage change. Those predicted blood concentrations could be used to estimate the corresponding dopamine D2/3 receptors (D2/3R) occupancy by antipsychotics based on the tight relationship between blood and brain pharmacokinetics. However, this 2-step prediction has never been tested. Methods. Two blood samples were collected at separate time points from 32 clinically stable outpatients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; mean ± SD age: 60.1±7.3 years) to measure plasma concentrations of olanzapine or risperidone at baseline. Then, subjects underwent a dose reduction of olanzapine or risperidone and completed a [11C]-raclopride positron emission tomography scan to measure D2/3R occupancy in the putamen. The plasma concentration at the time of the scan was predicted with the 2 samples based on population pharmacokinetic model, using NONMEM. D2/3R occupancy was then estimated by incorporating the predicted plasma concentration in a hyperbole saturation model. The predicted occupancy was compared to the observed value. Results. The mean (95% CI) prediction errors for the prediction of D2/3R occupancy were -1.76% (-5.11 to 1.58) for olanzapine and 0.64% (-6.18 to 7.46) for risperidone. The observed and predicted D2/3R occupancy levels were highly correlated (r = 0.67, P =. 001 for olanzapine; r = 0.67, P =. 02 for risperidone). Conclusions. D2/3R occupancy levels can be predicted from blood drug concentrations collected prior to dosage change. Although this 2-step model is subject to a small degree of error, it could be used to select oral doses aimed at achieving optimal D2/3R occupancy on an individual basis.

KW - antipsychotics

KW - dopamine

KW - olanzapine

KW - PET

KW - population pharmacokinetics

KW - prediction

KW - risperidone

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84954357476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954357476&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbv106

DO - 10.1093/schbul/sbv106

M3 - Article

C2 - 26221049

AN - SCOPUS:84954357476

VL - 42

SP - 212

EP - 219

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 1

ER -